Study of Nimotuzumab Combined with Chemotherapy Treatment for Metastatic Nasopharyngeal Carcinoma

Objective To evaluate the outcome and side-effect of nimotuzumab combined with gemcitabine chemotherapy for metastatic nasopharyngeal carcinoma. Methods Thirteen cases of metastatic nasopharyngeal carcinoma were included in this study.All patients received nimotuzumab (200 mg/w)combined with gemcitabine(1 000 mg/m2，d1，d8)regimen therapy， 21 days was one cycle.Their clinical response was assessed after 2 cycles of chemotherapy. Results There were 2 CR cases(15.2%)，6 PR cases(46.2%)，the total response rate(CR+PR)was 61.5%；1 year survival rate was 76.9%.Drug related toxic effect was I-Ⅱ grand bone narrow depression. Conclusion Nimotuzumab combined with gemcitabine has a better short-term efficacy in the treatment of patients with metastatic nasopharyngeal carcinoma，and the toxicities are acceptable.